# T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer

> **NCT01967823** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 11 (actual)

## Conditions studied

- Melanoma
- Meningioma
- Breast Cancer
- Non-Small Cell Lung Cancer
- Hepatocellular Cancer

## Interventions

- **BIOLOGICAL:** Anti-NY ESO-1 mTCR PBL
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **DRUG:** Aldesleukin

## Key facts

- **NCT ID:** NCT01967823
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10-24
- **Primary completion:** 2020-04-06
- **Final completion:** 2020-04-06
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2021-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01967823

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01967823, "T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01967823. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*